Nearly 50% of experts expect this to be the most promising innovation pipeline.
Immuno-oncology (IO) drugs are expected to revolutionize cancer treatment within the next five years, according to a recent study by GlobalData.
GlobalData found in its “State of the Biopharmaceutical Industry – 2025” survey that 41% of pharmaceutical industry professionals surveyed believe IO/cancer therapy is the most promising innovation pipeline area.
Urte Jakimaviciute said: “Advances in immunotherapies such as checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, etc. are revolutionizing the way cancer is treated. As these therapies are developed, they may lead to more effective and personalized treatments. .
“Added to this, the unmet need for many types of cancers that lack effective treatments for indications is driving and will continue to drive innovation in immuno-oncology/cancer treatment,” the expert added.
Anti-obesity medications were the second most popular choice (23%).
Anti-obesity drugs are expected to have a huge impact on the pharmaceutical industry in the next 12 months, Jakimaviciute said, citing a survey by GlobalData. The limited availability of effective treatments has spurred the need for innovative therapies, making this area an area of focus over the next five years.
GlobalData conducted the survey between November 15 and December 4, 2024, gathering insights from 128 industry professionals.
